Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
RESEARCH TOOLSreports
Holding CRBP?
Track your performance easily
CRBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.05 - $61.90
Previous Close$17.47
Volume181.19K
Average Volume (3M)660.51K
Market Cap
$212.78M
Enterprise Value$57.02M
Total Cash (Recent Filing)$159.36M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Mar 18, 2025EPS Estimate
-$1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.70
Shares Outstanding12,179,482
10 Day Avg. Volume361,749
30 Day Avg. Volume660,515
Standard Deviation0.55
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$69.80Price Target Upside288.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
PremiumCompany Announcements
Corbus Pharmaceuticals Reports Q3 2024 Financial Results
PremiumCompany Announcements
Corbus Pharmaceuticals Reveals Promising Obesity Treatment DataBulls Say, Bears Say
Bulls Say
Obesity Treatment InnovationCRB-913 achieved up to 38% weight loss in diet-induced obese mice at an 80 mg/kg/day dose, indicating substantial efficacy with reduced brain penetration.
Oncology Treatment AdvancementsCRB-701, an anti-nectin-4 antibody drug conjugate, is being investigated in patients with advanced solid tumors and has completed enrollment in its Phase 1 trial.
Safety And TolerabilityThe key takeaway for CRB-701 is that its efficacy appears comparable to Padcev in UC, but without causing peripheral neuropathy or rash, providing a safer and more tolerable option for patients.
Bears Say
Clinical Trial ConcernsThe imbalance and dose dependency in neuropsychiatric AEs seen in the treatment arm were the main cause for concern among investors.
Investor SentimentThe company has a high short interest percentage of 21.9%, which may indicate skepticism or concerns from investors.
Market ReactionCRBP shares are under significant pressure following news from Novo Nordisk/NVO of highly anticipated, top-line, 16-week, P2a data for monlunabant.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.05 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Currently, no data Available
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 112 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$0.952 by -$0.198.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -$1.24.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,179,482 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.15 in its last earnings report, missing expectations of -$0.952. Following the earnings report the stock price went down -2.062%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Among the largest hedge funds holding Corbus Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Corbus Pharmaceuticals’s shares valued at 3M.
---
Corbus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.80 (288.86% Upside)
$69.80 (288.86% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 77%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 171.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
306.27%
12-Months-Change
Fundamentals
Return on Equity
-51.32%
Trailing 12-Months
Asset Growth
352.47%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
CRBP Stock 12 Month Forecast
Average Price Target
$69.80
▲(288.86% Upside)
Technical Analysis
PAVmed
―
TRACON Pharmaceuticals
―
Cyclacel Pharmaceuticals
―
Karyopharm Therapeutics
―
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
+3.42%
reiterated a buy rating 20 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of +3.42% per trade.
---